Repare Therapeuticsの空売り状況は、投資家がRepare Therapeuticsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Repare Therapeutics (NASDAQ:RPTX) 株価情報, 空売り情報

REPARE THERAPEUTICS INC

Repare Therapeutics

Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.

Repare Therapeutics Inc

Pan American Silver (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PAAS#TSX">PAAS</a>) reported quarterly earnings of $0.42 per share which beat the analyst consensus estimate of $0.28 by 50 percent. This is a 4100 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $773.20 million which beat the analyst consensus estimate of $697.40 million by 10.87 percent. This is a 28.57 percent increase over sales of $601.40 million the same period last year.

Earnings

Earnings Beats

News

TSX:PAAS

Pan American Silver Q1 Adj. EPS $0.42 Beats $0.28 Estimate, Sales $773.20M Beat $697.40M Estimate

Cematrix (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CEMX#TSX">CEMX</a>) reported quarterly losses of $(0.01) per share. The company reported $6.63 million in sales this quarter.

TSX:CEMX

Cematrix Q1 EPS $(0.01), Sales $6.63M

Acadian Timber (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ADN#TSX">ADN</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.17 by 23.53 percent. This is a 40 percent decrease over earnings of $0.35 per share from the same period last year. The company reported quarterly sales of $24.83 million which beat the analyst consensus estimate of $22.40 million by 10.87 percent. This is a 13.80 percent decrease over sales of $28.81 million the same period last year.

TSX:ADN

Acadian Timber Q1 EPS $0.21 Beats $0.17 Estimate, Sales $24.83M Beat $22.40M Estimate

Streaming giant Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) continues to dominate the sector and its stock keeps <a href="https://www.benzinga.com/general/entertainment/25/04/44995039/netflix-ceo-says-streaming-company-saved-hollywood-as-stock-hits-new-all-time-highs">hitting all-time highs.</a>
Netflix isn't slowing down and is launching a major overhaul to its home page that could help user engagement.
What Happened: While Netflix didn't break out its subscriber figure in the<a href="https://www.benzinga.com/general/entertainment/25/04/44877995/netflix-crushes-q1-says-its-working-hard-to-improve-and-expand-its-offering"> latest quarterly results,</a> revenue growth likely led to more than 300 million paid subscribers and a gain from the end of 2024.
Netflix is ready to help those hundreds of millions of users remain engaged on the streaming platform and get better recommendations for what to watch.
The platform homepage on mobile will provide a TikTok-style vertical feed of clips and trailers from movies and shows, <a href="https://www.hollywoodreporter.com/business/business-news/new-netflix-homescreen-coming-soon-vertical-video-openai-1236208893/">according </a>to The Hollywood Reporter. Clicking on one of the clips takes a user to that movie or show.
"We've been constantly improving it over the last 12 years, mostly behind the scenes, but now, thanks to a combination of new technology and the expansion of our entertainment offerings, we think it's time to take a giant leap forward," Netflix Chief Product Officer Eunice Kim said of the home page.
Netflix is also using OpenAI to help with search recommendations for users in an effort to be "more responsive to your moods and interest in the moment.&#8221;
Chief Technology Officer Elizabeth Stone said the goal is for users to get recommendations using phrases like "I want something funny and upbeat" or "I want something scary, but not too scary" rather than just searching for a comedy or horror film.
Users will see popular titles and award-winning features more prominent on the platform home for TVs. Shortcuts to different categories will be moved from the left side of the screen to the top.
According to the report, the new home page is expected to be launched in the next few months.
Kim said the new experience will give the company more flexibility in the future.
"We are always going to keep sight of what we think is the best experience for our members, particularly driving discovery and engagement with all of the movies and shows and live events and games that they love."
Read Also: <a href="https://www.benzinga.com/general/entertainment/25/05/45200209/exclusive-netflix-customers-excited-for-original-movies-squid-game-stranger-things-nfl-60-say-this-tops-2025-must-watch-list">EXCLUSIVE: Netflix Customers Excited For Original Movies, &#8216;Squid Game,&#8217; &#8216;Stranger Things,&#8217; NFL: 60% Say This Tops 2025 Must-Watch List</a>
Why It's Important: Netflix continues to dominate the streaming space and sees strong engagement. The changes to the home page across mobile and TV will be a good test to see if user engagement increases.
Netflix already features its top-watched TV shows and movies in users&#8217; feeds, but the top hits could see a more prominent placement.
The streaming giant will also be able to show viral clips from shows and movies via the TikTok-style feed, which could see people clicking through to watch full episodes or the full movie, increasing overall minutes on the platform.
As Netflix builds out its live content, the streamer can also find new ways to highlight live content at the top of a feed and highlight events as they are currently happening.
NFLX Price Action: Netflix stock closed up 1.6% to $1,155.41 on Wednesday. The stock hit a new all-time high of $1,164.00 during Wednesday's trading session. Netflix stock is up 30.3% year-to-date in 2025 and up over 90% in the last year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/25/04/44905838/netflix-playing-offense-while-stock-plays-defense-6-analysts-on-q1-results-advertising-growth-ahead">Netflix &#8216;Playing Offense&#8217; While Stock Plays Defense: 6 Analysts On Q1 Results, Advertising Growth Ahead</a></li>
</ul>
Photo: Shutterstock

Entertainment

Trading Ideas

NFLX

Netflix Keeps Hitting New Highs: Can TikTok-Style Feed, OpenAI Search Power Even More Growth?

Management

Western Digital Names Kris Sennesael As Chief Financial Officer, Effective May 12, 2025.

Osisko Gold Royalties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OR#NYSE">OR</a>) reported quarterly earnings of $0.16 per share which met the analyst consensus estimate. This is a 33.33 percent increase over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $54.92 million which missed the analyst consensus estimate of $65.22 million by 15.80 percent. This is a 21.91 percent increase over sales of $45.05 million the same period last year.

Earnings Misses

Osisko Gold Royalties Q1 Adj. EPS $0.16, Inline, Sales $54.92M Miss $65.22M Estimate

WSP Global (TSX:<a class="ticker" href="https://www.benzinga.com/stock/WSP#TSX">WSP</a>) reported quarterly earnings of $1.76 per share which beat the analyst consensus estimate of $1.70 by 3.53 percent. This is a 13.55 percent increase over earnings of $1.55 per share from the same period last year. The company reported quarterly sales of $3.35 billion which beat the analyst consensus estimate of $3.30 billion by 1.42 percent. This is a 19.84 percent increase over sales of $2.79 billion the same period last year.

TSX:WSP

WSP Global Q1 Adj. EPS $1.76 Beats $1.70 Estimate, Sales $3.35B Beat $3.30B Estimate

Great-West Lifeco (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GWO#TSX">GWO</a>) reported quarterly earnings of $1.11 per share which missed the analyst consensus estimate of $1.14 by 2.63 percent. This is a 1.83 percent increase over earnings of $1.09 per share from the same period last year. The company reported $10.99 billion in sales this quarter. This is a 39.53 percent increase over sales of $7.88 billion the same period last year.

TSX:GWO

Great-West Lifeco Q1 Adj. EPS $1.11 Misses $1.14 Estimate, Sales $10.99B Up From $7.88B YoY

Nutrien (TSX:<a class="ticker" href="https://www.benzinga.com/stock/NTR#TSX">NTR</a>) reported quarterly earnings of $0.11 per share which missed the analyst consensus estimate of $0.30 by 63.33 percent. This is a 76.09 percent decrease over earnings of $0.46 per share from the same period last year. The company reported quarterly sales of $5.10 billion which missed the analyst consensus estimate of $5.15 billion by 0.97 percent. This is a 5.36 percent decrease over sales of $5.39 billion the same period last year.

TSX:NTR

Nutrien Q1 Adj. EPS $0.11 Misses $0.30 Estimate, Sales $5.10B Miss $5.15B Estimate

CORRECTION: APA Q1 Adj. EPS $1.06 Beats $0.83 Estimate, Sales $2.61B Beat $2.20B Estimate

Crombie REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CRR#TSX">CRR</a>) reported quarterly earnings of $0.30 per share. This is unchanged from the same period last year. The company reported $122.73 million in sales this quarter. This is a 3.48 percent increase over sales of $118.61 million the same period last year.

TSX:CRR

Crombie REIT Q1 FFO $0.30, Same YoY, Sales $122.73M Up From $118.61M YoY

Manulife Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MFC#TSX">MFC</a>) reported quarterly earnings of $0.99 per share which beat the analyst consensus estimate of $0.98 by 1.02 percent. This is a 5.32 percent increase over earnings of $0.94 per share from the same period last year. The company reported $2.14 billion in sales this quarter. This is a 14.26 percent increase over sales of $1.87 billion the same period last year.

TSX:MFC

Manulife Financial Q1 Adj. EPS $0.99 Beats $0.98 Estimate, Sales $2.14B Up From $1.87B YoY

Summit Midstream (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMC#NYSE">SMC</a>) reported quarterly losses of $(0.16) per share. The company reported $132.70 million in sales this quarter.

Summit Midstream Q1 EPS $(0.16), Sales $132.70M

Dividends

MTRN

Materion Announces It Raises Its Quarterly Dividend From $0.135/Shr To $0.14/Shr

Proficient Auto Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAL#NASDAQ">PAL</a>) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.09) by 33.33 percent. The company reported quarterly sales of $95.21 million which beat the analyst consensus estimate of $94.64 million by 0.59 percent. This is a 0.37 percent decrease over sales of $95.56 million the same period last year.

Proficient Auto Logistics Q1 EPS $(0.12) Misses $(0.09) Estimate, Sales $95.21M Beat $94.64M Estimate

&#xA9; Magnite &#x7C; → Widened typical guidance ranges for Q2, assumed some softening in the back half of Q2, related to higher risk verticals such as auto, retail and travel → Total Contribution ex-TAC(1) for Q2 2025 to be between $154 and $160 million → Contribution ex-TAC(1) attributable to CTV for Q2 2025 to be between $70 and $72 million → Contribution ex-TAC(1) attributable to DV+ for Q2 2025 to be between $84 and $88 million → Adjusted EBITDA operating expenses(2) for Q2 2025 to be between $110 and $112 million → Performance in Q2 to date has been in line with prior expectations; however, due to tariff-driven economic uncertainty, not reaffirming full-year 2025 expectations

Guidance

MGNI

Magnite Q2 Total Contribution ex-TAC Outlook Of $154.000M-$160.000M vs $163.14M Est

Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.06) by 1233.33 percent. This is a 700 percent decrease over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $9.83 million which missed the analyst consensus estimate of $10.91 million by 9.91 percent. This is a 161.93 percent increase over sales of $3.75 million the same period last year.

Myomo Q1 EPS $(0.80) Misses $(0.06) Estimate, Sales $9.83M Miss $10.91M Estimate

Compass Minerals Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>) raises FY2025 sales outlook from $1.08 billion-$1.20 billion to $1.16 billion-$1.25 billion vs $1.16 billion estimate.

Compass Minerals Intl Raises FY2025 Sales Guidance from $1.08B-$1.20B to $1.16B-$1.25B vs $1.16B Est

QGEN

QIAGEN To Elect Stephen H. Rusckowski As Chairman; To Succeed Lawrence A. Rosen

Orbit Garant Drilling (TSX:<a class="ticker" href="https://www.benzinga.com/stock/OGD#TSX">OGD</a>) reported quarterly earnings of $0.08 per share. This is a 60 percent increase over earnings of $0.05 per share from the same period last year. The company reported $50.00 million in sales this quarter. This is a 3.73 percent increase over sales of $48.20 million the same period last year.

TSX:OGD

Orbit Garant Drilling Q3 EPS $0.08 Up From $0.05 YoY, Sales $50.00M Up From $48.20M YoY

Press Releases

Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

Opinion

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Repare Therapeutics Announces Leadership Transitions

Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates

Comments

Repare Therapeutics

空売り

Repare Therapeutics (NASDAQ:RPTX) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル